SynthesisBioMed research international2019
Medical Cannabinoids for Cancer Cachexia: A Systematic Review and Meta-Analysis.
Synthesis in BioMed research international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 5 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Indications of Cannabinoids for the Palliation of Cancer-Associated Symptoms: A Systematic Review and Meta-Analysis.Current oncology reports · 2025Pooled it
- Cannabinoid interventions for improving cachexia outcomes in cancer: a systematic review and meta-analysis.Journal of cachexia, sarcopenia and muscle · 2022Pooled it
- The Effect of Cannabis-Based Medicine in the Treatment of Cachexia: A Systematic Review and Meta-Analysis.Cannabis and cannabinoid research · 2021Pooled it
- A Mapping Literature Review of Medical Cannabis Clinical Outcomes and Quality of Evidence in Approved Conditions in the USA from 2016 to 2019.Medical cannabis and cannabinoids · 2021Pooled it
- Roles of Cannabinoids in Melanoma: Evidence from In Vivo Studies.International journal of molecular sciences · 2020Pooled it
- A randomised, double blind, placebo-controlled trial of megestrol acetate or dexamethasone in treating symptomatic anorexia in people with advanced cancer.Scientific reports · 2021Trial
- Efficacy of Cannabinoids in Improving Nutritional Outcomes in Chemotherapy Patients: A Scoping Review.Cureus · 2026Review
- [Therapeutic indications in lawsuits seeking medical Cannabis in Brazil: a cross-sectional study in light of scientific evidence].Cadernos de saude publica · 2026Article
- Efficiency and safety of cannabinoid medical use: an analysis of discussions and observed trends on Instagram.Frontiers in public health · 2024Article
- Medical Cannabis Increases Appetite but Not Body Weight in Patients with Inflammatory Bowel Diseases.Nutrients · 2023Article
- Medicinal Cannabis and Implications for Workplace Health and Safety: Scoping Review of Systematic Reviews.Workplace health & safety · 2023Article
- Impacts of medical and non-medical cannabis on the health of older adults: Findings from a scoping review of the literature.PloS one · 2023Article
- The Effectiveness and Safety of Medical Cannabis for Treating Cancer Related Symptoms in Oncology Patients.Frontiers in pain research (Lausanne, Switzerland) · 2022Article
- Cannabinoids and their derivatives in struggle against melanoma.Pharmacological reports : PR · 2021Review
- The Peripheral Cannabinoid Receptor Type 1 (CBMolecules (Basel, Switzerland) · 2021Review
- Short-Term Medical Cannabis Treatment Regimens Produced Beneficial Effects among Palliative Cancer Patients.Pharmaceuticals (Basel, Switzerland) · 2020Article
- Targeting the endocannabinoid system: a predictive, preventive, and personalized medicine-directed approach to the management of brain pathologies.The EPMA journal · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesCancer cachexia (CCA) is an intractable and ineffective metabolic syndrome that attacks 50-80% of cancer patients. It reduces patient's life quality, affects the efficacy of treatment, and then increases their mortality; however, there are no established therapeutic strategies for CCA in the world. In this study, we assess the positive and negative effects of cannabinoid in the treatment of CCA.
methodsWe searched the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, MEDLINE, EMBASE, Web of Science, and PubMed up to December 2017.
resultsOf the 256 screened studies, three studies with a total of 592 participants were included. Compared with placebo, cannabinoid increased the appetite (MD 0.27, 95% CI -0.51 to 1.04; n= 3) but failed to improve the overall quality of life (QOL; MD -12.39, 95% CI [-24.21 to -0.57; n = 2), and a total of 441 patients had 607 adverse events (AEs; 496 in the cannabinoid group and 111 in the placebo group).
conclusionsOur analysis showed cannabinoid is effective in increasing appetite in cancer patients. However, it declines the quality of life, which may be due to the side effects of cannabinoid.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.